Syncom Formulations (India) Ltd. — Interim / Quarterly Report 2024

Nov 11, 2024

SYNCOM/SE/2024-25 11th November, 2024

Online filing at: www.listing.bseindia.com and

https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp

To, BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai (M.H.) 400 001 BSE CODE:524470

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai- 400051 NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015 - Submission of Standalone & Consolidated unaudited Financial Results along with Limited Review Report, Statement of Assets and Liabilities and Cash Flow for the quarter and half year ended on 30th September, 2024.

Dear Sir/Ma'am

This is in continuation of our letter no. SYNCOM/SE/2024-25 dated 4th November, 2024 regarding intimation of Board meeting for consideration and approval of Standalone and Consolidated Un-Audited Financial Results for the Quarter/ Half Year ended 30th September, 2024.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the following:

• 1. Standalone and Consolidated Un-Audited Financial Results of the Company for the Quarter/ Half Year ended on 30th September, 2024;
• 1. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Quarter/ Half Year ended on 30th September, 2024;
• 1. Standalone and Consolidated Un-Audited Statement of Assets and Liabilities for the Half Year ended on 30th September, 2024; and
• 1. Standalone and Consolidated Un-Audited Statement of Cash Flow for the Half year ended on 30th September, 2024.

which was considered and approved by the Board at their Meeting held on Monday, the 11thNovember, 2024 at 4:00 P.M. and Concluded at 5:15 P.M.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and the same shall also be hosted on the website of the company.

The Financial Results will also be published in widely circulated English and Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

The Board Meeting commenced at 4:00 P.M. and Concluded at 5:15 P.M.

You are requested to take on record the unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow along with Limited Review Report for your reference and record.

Thanking You, Yours Faithfully, For, SYNCOM FORMULATIONS (INDIA) LIMITED CS VAISHALI AGRAWAL COMPANY SECRETARY & COMPLIANCE OFFICER VAISHALI AGRAWAL Digitally signed by VAISHALI AGRAWAL Date: 2024.11.11 17:15:30 +05'30'

Encl: a/a

Regd.Off =« 7,Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-267, Sector - 1, Pithampur, Dist Dhar-454775

E Mail finance@silin, Website:- www.sfilIn, CIN - L24230MH1988PLCO47759

'STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30TH SEPTEMBER, 2024

	Particulars	Quarter Ended Yoar to date Ended				(Rs.In Lakhs) ( Except EPS)	Year Ended
S. No.
			30-09-2024 30-06-2024 30-09-2023 30-09-2024 30-09-2023 31-03-2024
			Unaudited Unaudited Unaudited Unaudited Unaudited				Audited
T	[Revenue from Operations	10149.26	8586.43	6238.68	1873568	12175.11	25835.95
2	Other Income	418.35	22797	400.35	646,32	588.09	1310.06
3	Totalincome (1+2)	10867.60	881440	6639.03	19382.00	12783.20	27146.02
T	[exensEs
	(8) Cost of materials consumed	6057.67	630313	325,08	1216070	5590.39	13152.91
	(5) Purchases of Stock-in-Trade ( ¢ ) Changes in inventories of finished goods, Stock-in- Trade	1260.24	408,08	81969	1666.32	1733.97	282083
	[and work-in-progress	(1560.63)	(263.29)	(0860	(1824.12)	81.93	(213.10)
	(¢) Employee benefts expanse	124039	1084.76	900.10	22515	1662.91	3505.77
	(#) Finance costs	18.22	38.65	107.67	54.87	21974	44487
	(1) Depreciation and amortization expense	130,00	13000	87.08	26000	197.08	nn
	(9) Other expenses	1158.89	1105.38	893.03	2264.27	1820.96	3989.12
	Total expenses (4)	9102.48	7804.71	582495	16907.19	11367.78	2396763
5§	[Profitiloss) before exceptional items and tax (3- 4)	1465.12	1009.69	814.08	247481	1395.42	3178.39
S	s __[Swipionsl	(0.24)		000	(0.24)	0.00	(239)
7	[Proftiioss) before tax (5-6)	1464.88		814.08	2474.57	1395.42	3176.00
T	[Taxexpense:	4855				0871
	(1) Current tax (2) Deferred tax	21.33	24377 306	14841 4512	592.32 24.39	41.31	75825 55.43
S	[Profit (Loss) for the period from continuing operations (7]
	5	1095.00	762.86	62055	1857.88	1045.40 T	2362.32
0 11	Proftioss) from Giscontinued operations Taxexpense of discontinued operations	050 000	000 000	000 0.00	550 0.00	0.00	T 0.00
12	[Profit(ioss) from Discontinued operations (after tax) (10-11)
		000	000	0.00	0.00	0.00	0.00
73	Profit{ioss) for the period (8 + 12)	1095.00	7T62.86	62055	1857.86	1045.40	236232
74	[Oter Comprenensive Income A tems that will not be reclassified to profit of loss	000	0.00	0.00	0.00	0.00	000
	(i) Income tax refating to items that will not be reclassified to
	proft or loss	0.00	000	0.00	000	000	0.0
	8 (1) hems that will be reciassified to profit or loss	39188	27593	12434	66781	ESRY	681.39
	i) Income tax relating to items that will be reclassified to profil had
15	Total Comprenensive Income for the period (XII+XIV)	0.00	000	0.00	0.00	0.0	0.00
	(Comprising Comprehensive Other (Loss) and Profit
	income for the period)	148688	1038.79	74489	252567	1376.51	304371
16	Paid up Share Capital of the Company (Face Value 17)	400,00	9400.00	9400.00	9400.00	9400.00	540000
17 18	Reserves excluding revaluation reserves Eamings per equity share (for continuing operation):	A	A				19245.18
			011				032
	(1) Basic (2) Diluted	0.16 o016	011	0.08 0.08	0.27 027	0.15 015	0
19	Eamings per equity share (for discontinued operation):
	(1) Basic	000	000	000	0.00	0.00	0.00
	(2) Diluted	0.00	000	000	0.00	000	0.00
20	Eamings per equity share (for discontinued & continuing operations)
	(1) Basic	016	011	008	0.27	01s	032
	(2) Dilvted	0.16	011	0.08	027	015	0.32

Date: 11-11-2024

Place: Indore For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda| Chairman & Wholetime Director| DIN: 00023050

Works:- 256-257, Sector - 1, Pithampur, Dist. Dhar-454775 E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN:-124239MH1988PLC047759

STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND YEARLY UNAUDITED RESULTS

	(Rs.In Lakhs) (Except EPS)
		Quarter Ended			Year to date Ended		Previous Year Ended
S. No.	Particulars	30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
٠	Segment Revenue
	a) Pharmaceuticals Drugs & Formulations	10218.43	8585.33	6255.88	18803.76	11815.29	25,672.79
	b) Trading of Commodities	251.10	132.41	286.04	383.51	743.02	1,071.34
	c) Renting of Property	98.07	96.66	97.11	194.73	204.89	401.89
	Total Segment Revenue	10567.60	8814.40	6639.03	19382.00	12763.20	27,146.02
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00
	Revenue from Operations	10567.60	8814.40	6639.03	19382.00	12763.20	27,146.02
$\overline{\mathbf{z}}$	Segment Results Profit(+)/Loss(-) before tax
	and interest from each segment
	a) Pharmaceuticals Drugs & Formulations	1382.69	955.36	823.70	2338.05	1419.68	3.232.76
	b) Trading of Commodities	8.40	4.39	5.38	12.79	$-0.32$	18.49
	c) Renting of Property	90.01	88.59	92.57	178.60	195.80	369.62
	Total Profit before tax	1481.10	1048.34	921.65	2529.44	1615.16	3,620.87
	Less: i) Interest	16.22	38.65	107.57	54.87	219.74	444.87
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00	0.00	0.00
	Profit before tax	1464.88	1009.69	814.08	2474.57	1395,42	3,176.00
з	(Segment Asset-Segment Liabilities)
	Segment Asset
	a) Pharmaceuticals Drugs & Formulations	31234.08	29437.25	34624.25	31234.08	34624.25	33,390.18
	b) Trading of Commodities	971.86	964.42	1063.79	971.86	1063.79	1,026.45
	c) Renting of Property	4733.45	4733.45	4733.45	4733.45	4733.45	4733.45
	Total Segment Asset	36939.39	35135.12	40421.49	36939.39	40421.49	39,150.08
	Un-allocable Assets	0.00	0.00	0.00	0.00	0.00	0.00
	Net Segment Asset	36939.39	35135.12	40421.49	36939.39	40421.49	39,150.08
	Seament Liabilities
	a) Pharmaceuticals Drugs & Formulations	5432.16	5050.13	13155.03	5432.16	13155.03	10.181.37
	b) Trading of Commodities	243.87	167.45	131.38	243.87	131.38	151.93
	c) Renting of Property	92.52	181.32	163.44	92.52	163.44	171.60
	Total Segment Liabilities	5768.55	5398.90	13449.85	5768.55	13449.85	10,504.90
	Un-allocable Liabilities	0.00	0.00	0.00	0.00	0.00
	Net Segment Liabilities	5768.55	5398.90	13449.85	5768.55	13449.85	10,504.90

1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11/11/2024.

These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read
2 with Companies (Indian Accountin

The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as 3 required.

The Standalone Statement of Assets and Liabilities as at 30th September, 2024 and the Standalone Statement of Cash Flow is provided as an annexure to this statement.

As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th September 2024. The report
5 does not have any impact on the a

6 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

Place: Indore

$\overline{\mathbf{4}}$

Date: 11/11/2024

For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankd Chairman & Wholetime Directo

DIN: 00023050

SYNCOM FORMULATIONS (INDIA) LIMITED
Regd Of - 7.Nira Industria Estate, Off Mahakal Caves Road Andhet (E) Mumbai-400093
	Works - 260-267, Sector - 1, Pithampur, Dist Dhar-454775
E Mol fnance@sfi n, Wabsil - www fiin, CIN - L24230MH1988PLC047750
Standalone Statement of Ass¢	Liabilities as st 30/09/2024
Particulars	Rs.In Lacs	30-09-2024 unaudited	31-03-2024 Audited
[ASSETS
Non-current assets
(a) Property, Plant and Equipment		6,009.22	7,230.60
(b) Capital Work in Progress		14211	-
(c) Intangible assets		472	11.05
(d) Investment Property		4,733.44	4,733.44
(e) Financial Assets		-
(i) Investments		558.69	251.92
(ii) Fixed Deposits & Accrued Interest		15.77	586.64
(iii) Deposits		56.85	51.80
(f) Other Non Current Assets		49.56	20.56
Current assets
(a) Inventories (b) Financial Assets		4,505.31	2,108.15
(i) Investments		- 8,012.38	6,369.94
(ii) Trade Receivables		8,662.76	9,321.46
: (iii) Cash And Cash Equivalents		21.73	6,335.05
(iv) Bank Balances other than (iii) above		1,163.16	448.21
(v) Deposits		340.14	412.00
(vi) Loans & Advances		542.59	429.33
(d) Other Current Assets		1,130.96	839.83
Total		36,939.39	39,150.08
[EQUITY AND LIABILITIES
Equity
(a) Equity Share Capital (b) Other Equity		9,400.00 21,770.84	9,400.00 19,245.18
Liabilities Non Current Liabilities		-
(a) Financial Liabilities		-
(i) Trade and other Deposits		- 92.52	171.60
(b) Provisions		370.44	330.38
(c) Deferred Tax Liabilities (Net)		522.06	497.67
Current liabilities
(a) Financial liabilities		+ 2
(i) Borrowings		1,367.21	7,165.03
(ii) Trade Payables		-
Dues Total Outstanding of Micro Enterprises and Small Enterprises.		493.64	586.77
Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises		1,843.03	836.33
(i) Other Financial Lial		219.57	213.62
(b) Other Current Liabilities		551.57	358.04
(c) Provisions		308.51	345.46
Total		36,939.39	39,150.08

Date: 11/11/2024

Place: Indore For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda Chairman & Wholetime Director DIN: 00023050

SYNCOM FORMULATIONS (INDIA) LIMITED
Regd.Off :- 7, Niraj Industrial Estate.Off Mahakali Caves Road.Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist. Dhar-454775
E Mail - finance@sfil.in, Website - www.sfil.in, CIN :- L24239MH1988PLC047759
Standalone Cash Flow Statement for the half year ended 30/09/2024
Particulars	30-09-2024	31-03-2024
Rs. In Lacs	unaudited	Audited
Cash Flow from Operating Activities Profit before extraordinary item and tax	2.474.81	3,178.39
Adjustments for,
Gain on Sale of Machinery / (Loss on Sale of Vehicle)	(0.24)	(2.39)
Gain/(Loss) on Actuarial valuation of employee benefits	(9.24)	(18, 50)
Depreciation	260.00	472.23
Depreciation Written Back		(1.74)
Finance Costs	54.87	444.87
Other Income	(636.91)	(1, 221.35)
Operating Profit before working capital changes	2,143.29	2,851.51
Changes in Working Capital
Inventory	(2,397,16)	(30.76)
Trade Receivables Loans & Advances	658.70	(1,807.63)
Other Current Assets	(113.26) (219.27)	(151.33) (128.37)
Trade Payables	913.57	(617.75)
Other Financial Liabilities	5.95	11.44
Other Current Liabilities	193.53	(47.21)
Short Term Provisions	(36.95)	84.59
Changes in Working Capital	(994.89)	(2,687.02)
Cash Generated from Operations before Tax	1,148.40	164.49
Less: Income Tax Paid	592.32	758.25
Net Cash From Operating Activities	556.08	(593.76)
Cash Flow from Investing Activities
Change in Property Plant and Equipment, Intangible Assets and Capital	(164.40)	(813.64)
Work in Progress Change in Investment Property
Change in Fixed Deposit & Accrued Interest	(144.08)	7,313.19
Change in Deposits	(4.95)	(2.15)
Change in Other Non Current Assets	(29.00)	155.58
Change in Trade & Other Deposits	(79.08)	17.46
Other Income	636.91	1,221.35
Change in Investment	(1, 272.16)	491.17
Net Cash from Investing Activities	(1,056.76)	8,382.96
Cash Flow from Financing Activities
Finance Costs	(54.87)	(444.87)
Change in Long Term Liabilities	10.06
Issue of Warrants & Share capital
Dividend Paid Borrowings
	(5,797.82)	(1, 153.12)
Net Cash from Financing Activities	(5,812.63)	(1, 536.85)
Net Decrease in Cash & Cash Equivalents	(6,313.32)	6,252.35
Cash & Cash Equivalents at the beginning of the Period	6,335.05	82.70
Cash & Cash Equivalents at the End of Period	21.73	6,335.05
Place: Indore	For, Syncom Formulations (India) Limited
Date: 11/11/2024
	Kedarmal Shankarlal Bankda

Chairman & Wholetime Director
DIN: 00023050

Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Half Year ended 30" September, 2024 pursuant to Regulation 33 of the SEBI (LODR) Regulations, ²⁰¹⁵

To, The Board of Directors SYNCOM FORMULATIONS (INDIA) LIMITED Indore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company"), for the period ended September, 30, 2024 ('the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015,including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta &Associates (Partner) M. No. 079452 UDIN: 24079452BJZZEQ9853

Place: Indore Date: 11" November 2024 CA Manish Mittal

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30TH SEPTEMBER, 2024

	(Rs.In Lakhs) (Except EPS)
S. No.	Particulars		Quarter Ended Year to date Ended				Year Ended
		30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
٦	Revenue from Operations	10231.42	8628.88	6383.89	18860.30	12367.47	26338.71
$\overline{2}$	Other Income	414.92	230.50	399.74	645.42	587.21	1352.59
з	Total Income $(1 + 2)$	10646.34	8859.38	6783.63	19505.72	12954.68	27691.30
$\overline{\phantom{a}}$	EXPENSES
	(a) Cost of materials consumed	6857.57	5303.13	3325.08	12160.70	5590.39	13152.91
	(b) Purchases of Stock-in-Trade	1266.24	428.61	837.11	1694.85	1758.53	2710.59
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	(1543.72)	(280.40)	(251.75)	(1824.12)	116.47	(175.46)
	(d) Employee benefits expense	1240.39	1084.76	900.10	2325.15	1662.91	3505.77
	(e) Finance costs	15.96	39.03	107.57	54.99	219.74	447.41
	(f) Depreciation and amortization expense	130,00	130.00	87.88	260.00	197,88	472.23
	(g) Other expenses	1194.83	1144.04	932.73	2338.87	1952.58	4180.16
	Total expenses (4)	9161.27	7849.17	5938.72	17010.44	11498.50	24293.61
5	Profit/(loss) before exceptional items and tax (3-4)	1485.07	1010.21	844.91	2495.28	1456.18	3397.69
6	Exceptional Items	0.00	0.00	0.00	(0.24)	0.00	(2.39)
$\overline{\mathbf{r}}$	Profit/(loss) before tax (5-6)	1485.07	1010.21	844.91	2495.04	1456.18	3395.30
8	Tax expense:
	(1) Current tax (2) Deferred tax	352.92 21.33	243.90 3.06	148.62 45.12	596.82 24.39	324.07	808.45
$\overline{9}$	Profit (Loss) for the period from continuing operations (7-8)					41.31	55.43
		1110.82	763.25	651.17	1873.83	1090.80	2531.42
10 11	Profit/(loss) from discontinued operations Tax expense of discontinued operations	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)						0.00
		0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9+12)	1110.82	763.25	651.17	1873.83	1090.80	2531.42
14	Other Comprehensive Income A(i) Items that will not be reclassified to profit or loss
	(ii) Income tax relating to items that will not be reclassified to profit	0.00	0.00	0.00	0.00	0.00	0.00
	or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	391.88	275.93	124.34	667.81	331.11	681.39
	(ii) Income tax relating to items that will be reclassified to profit or loss
15	Total Comprehensive Income for the period (XIII+XIV)	0.00	0.00	0.00	0.00	0.00	0.00
	Comprising Profit (Loss) and Other Comprehensive Income for
16	the period)	1502.70	1039.18	775.51	2541.64	1421.91	3212.81
17	Paid up Share Capital of the Company (Face Value 1/-) Reserves excluding revaluation reserves	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
18	Earnings per equity share (for continuing operation);						19414.28
	(1) Basic	0.16	0.11	0.08
	(2) Diluted	0.16	0.11	0.08	0.27 0.27	0.15 0.15	0.34 0.34
19	Earnings per equity share (for discontinued operation):
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)
	(1) Basic	0.16	0.11	0.08	0.27	0.15	0.34
	(2) Diluted	0.16	0.11	0.08	0.27	0.15	0.34

Place: Indore

Date: 11/11/2024

For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda Chairman & Wholetime Director DIN: 00023050

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093 Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail: - finance@sfil.in, Website: - www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND YEARLY UNAUDITED RESULTS

						(Rs.In Lakhs) (Except EPS)
		Quarter Ended			Year to date Ended	Previous Year Ended
S. No.	Particulars	30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue
	a) Pharmaceuticals Drugs & Formulations	1029807	8630.31	6401.08	18928.38	12007.67	26,218.06
	b) Trading of Commodities	251.10	132.41	286.04	383.51	743.02	1.071.34
	c) Renting of Property	97.17	96.66	96.51	193.83	203.99	401.89
	Total Segment Revenue	10646.34	8859.38	6783.63	19505.72	12954.68	27,691.29
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00
	Revenue from Operations	10646.34	8859.38	6783.63	19505.72	12954.68	27,691.29
2	Segment Results Profit(+)/Loss(-) before tax
	and interest from each segment
	a) Pharmaceuticals Drugs & Formulations	1403.29	956.25	855.13	2359.54	.1481.34	3.454.60
	b) Trading of Commodities	8.40	4.39	5.38	12.79	$-0.32$	18.49
	c) Renting of Property	89.11	88.59	91.97	177.70	194.90	369.62
	Total Profit before tax	1500.80	1049.23	952.48	2550.03	1675.92	3,842.71
	Less: i) Interest	15.96	39.03	107.57	54.99	219.74	447.41
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00	0.00
	Profit before tax	1484.84	1010.20	844.91	2495.04	1456,18	3,395.30
$\mathbf{3}$	(Segment Asset-Segment Liabilities)
	Segment Asset
	a) Pharmaceuticals Drugs & Formulations	31539.20	29849.25	34572.02	31539.20	34572.02	34,706.49
	b) Trading of Commodities	971.86	964.42	1063.79	971.86	1063.79	1,026.45
	c) Renting of Property	4733.45	4733.45	4733.45	4733.45	4733.45	4,733.45
	Total Segment Asset	37244.51	35547.12	40369.26	37,244.51	40,369.26	40,466.39
	Un-allocable Assets	0.00	0.00	0.00	0.00	0.00	0.00
	Net Seament Asset	37244.51	35547.12	40369.26	37,244.51	40,369.26	40,466.39
	Segment Liabilities
	a) Pharmaceuticals Drugs & Formulations	5552.20	5241.86	13057.38	5552.20	13057.38	11,328.58
	b) Trading of Commodities	243.87	167.45	131.38	243.87	131.38	151.93
	c) Renting of Property	92.52	181.32	163.44	92.52	163.44	171.60
	Total Segment Liabilities	5888.59	5590.63	13352.20	5888.59	13352.20	11,652.11
	Un-allocable Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
	Net Segment Liabilities	5888.59	5590.63	13352.20	5,888.59	13,352.20	11,652.11

Notes:-

1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11/11/2024.

2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.

4 The Consolidated Statement of Assets and Liabilities as at 30th September, 2024 and the Standalone and Consolidated Statement of Cash Flow is provided as an annexure to this statement.

5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

6 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th September, 2024. The report does not have any impact on the

For, Syncom Formulations (India) Limited

Place: Indore Date: 11/11/2024

Kedarmal Shankarlal Bankda Chairman & Wholetime Directo DIN: 00023050

Regd Off - 7,Niraj Industrial € state, Off Mahakal Caves Road Andherl (E) Mumbai-40003

Works « 266-267, Sector + 1, Pihampu, Dist Dhar-454775

€ Mal« finance@sfil in, Websita « wivw sfilin, CIN « L24230MN1088PLC047750.

Consoldated Statement of A	Jabilities a9 ot 3010912024
Particulars	30-09-2024	31-03-2024
Rs. In Lacs	unaudited	Audited
ASSETS
Non-current assets
(a) Property, Plant and Equipment	6,999.22	7,230.60
(b) Capital Work in Progress	142.11	-
(c) Intangible assets	4.72	11.05
(d) Investment Property	4,733.44	4733.44
(e) Financial Assets	-	-
(i) Investments	555.69	248.92
(ii) Fixed Deposits & Accrued Interest	120.80	691.67
(iii) Deposits	56.85	51.90
(f) Other Non Current Assets	49.56	20.56
Current assets	®	-
(a) Inventories	4,505.31	2,108.15
(b) Financial Assets	-	-
(i) Investments	8,012.38	6,369.94
(ii) Trade Receivables	8,824.32	10,329.84
(iii) Cash And Cash Equivalents	25.02	6,338.34
(iv) Bank Balances other than (iii) above	1,163.16	44821
(v) Deposits	340.14	412.00
(vi) Loans & Advances	542.63	427.78
(d) Other Current Assets Total	1,169.16 37,244.51	1,043.99 40,466.39
EQUITY AND LIABILITIES
Equity
(a) Equity Share Capital	9,400.00	9,400.00
(b) Other Equity	21,955.91	19,414.28
Liabilities	#	B
Non Current Liabili	-	-
(2) Financial Liabilities	=	-
(i) Trade and other Deposits	92.52	171.60
(b) Provisions	370.44	330.38
(c) Deferred Tax Liabilities (Net) Current liabilities	522.06	497.67
	-	-
(a) Financial liabilities (i) Borrowings	-	v
	1,424.60	7,248.66
(ii) Trade Payables Total Outstanding Dues of Micro Enterprises and Small Enterprises	- 49364	- 504.34
Total Oustanding Dues of Creditors other than Mcro Enterprises and Smal Enterprises	1,844.07	1,820.05
(iii) Other Financial Liabilities	219.57	213.62
(b) Other Current Liabilities	622.36	412.70
(c) Provisions	299.34	363.09
Total	37,244.51	40,466.39

Date: 11/11/2024

Place: Indore For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda Chairman & Wholetime Director DIN: 00023050

@ SYNCOM FORMULATIONS (INDIA) LIMITED RO Al Bt OF Mo A v Rood Arhod 6 Works e o = - 266.267, Sactor - 1, Pithampur, Dist Dhar-484775 nann i,	o 0003
s Consolidated Cash Flow Statamant for the half year andad 30/06/2024	AL, OB » LALLM HHOLCOTI00
Particulars Re. In Lacs	30-09-2024 unaudited	31-03-2024 Audited
[Profit before extraordinary tem and tax	249528	330760
Adiustments for, Gain on Sale of Machinery / (Loss on Sale of Vehicle)	(0.24)	(2.39)
(Gain/(Loss) on Actuarial valuation of employee benefits	(9.24)	3
Depreciation	26000	47223
[Depreciation Written Back	¥	(1.74)
Finance Costs	5460	4741
Other Income	(636.01)	(1,263.89)
Changes Operating Profit before working capital changes in Working Capital	7,164.78	304032
Inventory	(2,397.16)	1188
Trade Receivables	150552	(2.779.13)
Loans & Advances	(114.85)	(151.21)
Other Current Assets	(5331)	(324.29)
Trade Payables	(76.68)	60.70
Other Financial Liabilites	595	144
Other Current Liabilities	20966	(76.39)
Short Term Provisions	(63.75)	101.18
Changes in Working Capital	(984.62)	(283.70)
Cash Generated from Operations before Tax	1.180.16	21262
Less: Income Tax Paid	595.62	808.45
Net Cash From Operating Activities	583.34	(595.83)
Investing from Activi
Change in P Plant and Equipment, Intangible Assets and Capital Frety o Pm':'::;" G (Change in Investment Property	(164.40)	(@1369)
[Change in Fixed Deposit & Accrued Interest	-	s
Change in Deposits	(144.08)	7.208.16
	(4.95)	(@.19)
(Change in Other Non Current Assets Change in Trade & Other Deposits	(29.00)	155.58 1748
Other Income	(79.08)	128388
Change in Investment	636.01 (1.272.16)	47267
Net Cash from Investing Activities	(1,057.66)	830156
Cash Flow from Financina Activities Finance Costs		(447.41)
Change in Long Term Liabilties	(54.99) 4006	6114
issue of Warrants & Share capital
Dividend Paid
Borrowings	- (5624.08)	- (1.089.49)
Net Cash from Financing Activities	(5,838.99)	(1,455.76)
[Net Decrease in Cash & Cash Equivalents	(6:313.31)	6,250.37
Cash & Cash Equivalents at the beginning of the Period	6.338.34	8797
Cash & Cash Equivalents at the End of Period	25.03	633834
Place: Indore	For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda Chairman & Wholetime Director DIN: 00023050

SANJAY MEHTA & ASSOCIATES 338, Saket Nagar, Indore - 452 018 (M.P.)

Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and Half Year ended 30" September, 2024 pursuant to Regulation 33 of the SEBI (LODR) Regulations, ²⁰¹⁵

To, The Board of Directors SYNCOM FORMULATIONS (INDIA) LIMITED Indore (M.P.)

• 1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of SYNCOM FORMULATIONS (INDIA) LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended September 30, 2024 ("the Statement™), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.
• 1. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

S. No.	Name of the Company	Relationship with the
		Holding Company
	1. Sante Biotech Pvt. Ltd.	Wholly Owned Subsidiary
	2. Synmex Pharma Pvt. Ltd.	Wholly Owned Subsidiary
	3. Vincit Biotech International Pvt. Ltd.	Wholly Owned Subsidiary

1. The Statement includes the results of the following entity:

1. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015,including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta & Associates Chartered Accountants

FRN: 011524 (Partner) M. No. 079452 UDIN: 24079452BJZZER1565

Place: Indore :iA. Date: 11 November 2024 CA Manish Mittal \"g